Screening of pH-responsive long-circulating polysaccharide–drug conjugate nanocarriers for antitumor applications (original) (raw)
* Corresponding authors
a Key Laboratory of Sensing Technology and Biomedical Instrument of Guangdong Province, School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
E-mail: kangyang0543092016@163.com, wujun29@mail.sysu.edu.cn
b Department of Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
E-mail: pangjun530@163.com
c Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
d The True Light Middle School in Guangzhou, Liwan District, Guangzhou, China
Abstract
For the treatment of malignant tumors, drug nanocarriers with long blood circulation time and ability to target the tumor microenvironment are promising therapeutic abilities. In this work, to systematically investigate the roles and functions of polysaccharides as drug nanocarriers targeting the tumor microenvironment, different types of polysaccharides (alginic acid (Alg), hyaluronic acid (HA), and dextran (Dex)) were covalently bonded with doxorubicin (DOX) through a Schiff base reaction to form a pH-sensitive polysaccharide–DOX prodrug having an acid-sensitive imine bond. After screening, Dex-DOX exhibited high drug loading content and good stability, while Alg-DOX and HA-DOX may have disadvantages such as low degree of oxidation, limited drug loading capacity, or instability in physiological conditions. Dex-DOX prodrugs were able to self-assemble into stable nanoparticles in phosphate buffered saline (PBS). Then, Dex6k-DOX and Dex150k-DOX were selected for further comparisons since they had similar drug-binding rates and long circulation time. When compared with Dex6k-DOX, the longer main-chain Dex150k-DOX showed a higher drug release rate under simulated acidic conditions in vitro, which significantly inhibited cell proliferation. Further in vivo experiments showed that Dex150k-DOX could more effectively improve the antitumor efficiency and survival rate while reducing side-effects. Overall, the screening and comparisons provided detailed and systematical information about the polysaccharide–DOX prodrug platform as potential antitumor drugs.
You have access to this article
Please wait while we load your content... Something went wrong. Try again?
Supplementary files
Article information
DOI
https://doi.org/10.1039/C8TB02474J
Article type
Paper
Submitted
19 Sep 2018
Accepted
27 Nov 2018
First published
29 Nov 2018
Download Citation
J. Mater. Chem. B, 2019,7, 251-264
Permissions
Screening of pH-responsive long-circulating polysaccharide–drug conjugate nanocarriers for antitumor applications
X. Zhang, D. Li, J. Huang, K. Ou, B. Yan, F. Shi, J. Zhang, J. Zhang, J. Pang, Y. Kang and J. Wu,J. Mater. Chem. B, 2019, 7, 251DOI: 10.1039/C8TB02474J
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.